Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole for Secondary Prophylaxis of IFI in Allogeneic SCT Patients
NCT00143312Phase 4Completed
- Sponsor
- Pfizer
- Start
- Feb 2005
- Primary completion
- Apr 2008
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 4, open-label, single-arm trial of voriconazole in invasive fungal infection (IFI), sponsored by Pfizer. Primary endpoint: Occurrence of Proven or Probable Invasive Fungal Infection at 12 months. Started Feb 2005; status: completed.
02
Drugs
voriconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00143312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143312.